Generics drive down semaglutide prices in India.
Indian pharmaceutical companies are preparing to launch generic versions of semaglutide, a drug used for weight management and diabetes, following the expiration of patents. This development is expected to drive down prices and increase accessibility of the medication in the Indian market.
According to reports, over a dozen drugmakers are planning to enter the market, with monthly treatment costs potentially starting as low as ₹1,290. This is a significant reduction compared to the prices of branded versions, which could make the drug more affordable for a larger segment of the population.
The availability of lower-cost generics is anticipated to intensify competition within the weight-loss segment, benefiting consumers through increased choice and affordability. The entry of multiple players could also lead to further innovations and improvements in drug formulations and delivery methods.
Semaglutide, originally developed by Novo Nordisk, has gained popularity for its effectiveness in weight management and diabetes control. The introduction of generics in India could have a substantial impact on public health by providing a more accessible treatment option for individuals struggling with obesity and related conditions.
About the Author
